135 related articles for article (PubMed ID: 2372769)
1. Plasma prolactin as an indicator of disease progression in advanced breast cancer.
Bhatavdekar JM; Shah NG; Balar DB; Patel DD; Bhaduri A; Trivedi SN; Karelia NH; Ghosh N; Shukla MK; Giri DD
Cancer; 1990 May; 65(9):2028-32. PubMed ID: 2372769
[TBL] [Abstract][Full Text] [Related]
2. Plasma prolactin levels in patients with breast cancer.
Rose DP; Pruitt BT
Cancer; 1981 Dec; 48(12):2687-91. PubMed ID: 7306924
[TBL] [Abstract][Full Text] [Related]
3. Use of serum prolactin for monitoring the therapeutic response in ovarian malignancy.
Jha P; Farooq A; Rao DL; Agarwal N; Buckshee K
Int J Gynaecol Obstet; 1991 Sep; 36(1):33-8. PubMed ID: 1683299
[TBL] [Abstract][Full Text] [Related]
4. Relation between tumour size and plasma prolactin levels in premenopausal patients with breast carcinoma. A preliminary report.
Olsson H; Ewers SB; Landin-Olsson M; Ranstam J
Acta Radiol Oncol; 1985; 24(1):57-9. PubMed ID: 2984903
[TBL] [Abstract][Full Text] [Related]
5. [Prolactin and human cancer of the breast. I. Levels of correlation].
Cueto Ladrón de Guevara J; Villalba Moreno J; García Puche JL; Pedraza V
Rev Esp Oncol; 1985; 32(3):439-58. PubMed ID: 3870536
[TBL] [Abstract][Full Text] [Related]
6. [Plasma-prolactin concentrations in breast cancer at various stages, in mastopathy and other malignant tumors].
Holtkamp W; von Heyden D; Rauschecker H; Nagel GA
Schweiz Med Wochenschr; 1983 Oct; 113(41):1513-20. PubMed ID: 6635641
[TBL] [Abstract][Full Text] [Related]
7. Peptide and steroid hormone levels in pre- and postmenopausal breast carcinoma.
Bhatavdekar JM; Shah NG; Trivedi SN; Karelia NH
Neoplasma; 1987; 34(1):95-9. PubMed ID: 3104809
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal autoantibody responses against tumor-associated antigens decrease in breast cancer patients according to treatment modality.
Evans RL; Pottala JV; Nagata S; Egland KA
BMC Cancer; 2018 Jan; 18(1):119. PubMed ID: 29386014
[TBL] [Abstract][Full Text] [Related]
9. Comparison of plasma prolactin and CEA in monitoring patients with adenocarcinoma of colon and rectum.
Bhatavdekar JM; Patel DD; Giri DD; Karelia NH; Vora HH; Ghosh N; Shah NG; Trivedi SN; Balar DB
Br J Cancer; 1992 Nov; 66(5):977-80. PubMed ID: 1419646
[TBL] [Abstract][Full Text] [Related]
10. Effect of exosome biomarkers for diagnosis and prognosis of breast cancer patients.
Wang M; Ji S; Shao G; Zhang J; Zhao K; Wang Z; Wu A
Clin Transl Oncol; 2018 Jul; 20(7):906-911. PubMed ID: 29143228
[TBL] [Abstract][Full Text] [Related]
11. Endocrine status in stage II vs. advanced premenopausal and postmenopausal breast cancer patients.
Bhatavdekar JM; Patel DD; Shah NG; Giri DD; Vora HH; Karelia NH; Trivedi SN; Ghosh N; Suthar TP
Neoplasma; 1992; 39(1):39-42. PubMed ID: 1388248
[TBL] [Abstract][Full Text] [Related]
12. Serum hormones in human breast cancer subjects.
Krishnamoorthy G; Govindarajulu P; Ramalingam V
Neoplasma; 1989; 36(2):221-31. PubMed ID: 2497392
[TBL] [Abstract][Full Text] [Related]
13. [Decreased plasma zinc levels in metastatic breast cancer].
Holtkamp W; Thiery J; Rauschecker H; Nagel GA; Reis HE
Onkologie; 1990 Jun; 13(3):207-9. PubMed ID: 2204008
[TBL] [Abstract][Full Text] [Related]
14. Ipsilateral breast tumor recurrence as a predictor of distant disease: implications for systemic therapy at the time of local relapse.
Haffty BG; Reiss M; Beinfield M; Fischer D; Ward B; McKhann C
J Clin Oncol; 1996 Jan; 14(1):52-7. PubMed ID: 8558220
[TBL] [Abstract][Full Text] [Related]
15. Plasma fibrinogen level may be a possible marker for the clinical response and prognosis of patients with breast cancer receiving neoadjuvant chemotherapy.
Mei Y; Liu H; Sun X; Li X; Zhao S; Ma R
Tumour Biol; 2017 Jun; 39(6):1010428317700002. PubMed ID: 28621233
[TBL] [Abstract][Full Text] [Related]
16. Plasma lipids and prolactin in patients with breast cancer.
Bani IA; Williams CM; Boulter PS; Dickerson JW
Br J Cancer; 1986 Sep; 54(3):439-46. PubMed ID: 3756079
[TBL] [Abstract][Full Text] [Related]
17. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
[TBL] [Abstract][Full Text] [Related]
18. Can plasma prolactin predict tamoxifen resistance in patients with advanced breast cancer?
Bhatavdekar JM; Patel DD; Karelia NH; Shah NG; Ghosh N; Vora HH; Suthar TP; Balar DB; Doctor SS
Eur J Surg Oncol; 1994 Apr; 20(2):118-21. PubMed ID: 8181575
[TBL] [Abstract][Full Text] [Related]
19. Hyperprolactinemia is an indicator of progressive disease and poor prognosis in advanced breast cancer.
Holtkamp W; Nagel GA; Wander HE; Rauschecker HF; von Heyden D
Int J Cancer; 1984 Sep; 34(3):323-8. PubMed ID: 6480153
[TBL] [Abstract][Full Text] [Related]
20. Plasma melatonin in patients with breast cancer.
Falkson G; Falkson HC; Steyn ME; Rapoport BL; Meyer BJ
Oncology; 1990; 47(5):401-5. PubMed ID: 2216295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
